Prothena Corporation plc
PRTA
Market Cap$1.11B
Close$
$35.32
71.8% upside
Current Fair Value
71.8% upsideUndervalued by 71.8% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $1.11 Billion |
|---|---|
| Enterprise Value | $486.20 Million |
| Dividend Yield | $0.0 (0.0%) |
| Earnings per Share | $-2.76 |
| Beta | 1.36 |
| Outstanding Shares | 53,720,455 |
| Avg 30 Day Volume | 586,235 |
Return
| Return on Equity | - |
|---|---|
| Return on Assets | - |
| Return on Invested Capital | - |
Valuation & Multiples
| P/E Ratio | -7.52 |
|---|---|
| PEG | 0.65 |
| Price to Sales | 20.56 |
| Price to Book Ratio | 2.06 |
| Enterprise Value to Revenue | 5.32 |
| Enterprise Value to EBIT | -2.55 |
| Enterprise Value to Net Income | -4 |
| Total Debt to Enterprise | 0 |
| Debt to Equity | 0 |
Revenue Sources
No data
ESG Score
No data
About Prothena Corporation plc
7 employees
CEO: Gene Kinney Prothena Corporation plc is a late-stage clinical company with expertise in protein dysregulation and a diverse pipeline of novel investigational therapeutics with the potential to change the course of devastating neurodegenerative and r...